Diabetes mellitus among parkinsonian patients treated chronically with clozapine

Parkinsonism and Related Disorders

Volumn 10, Issue 7, 2004, Pages 439-441

  Fernandez, Hubert H ^a,e   Friedman, Joseph H ^b   Cecilia Lansang, M ^c   Factor, Stewart A ^d   Molho, Eric S ^d   Jim Coskun, D ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b BROWN UNIVERSITY   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e McKnight Brain Institute   (United States)

Author keywords

Clozapine; Diabetes mellitus; Parkinson's disease

Indexed keywords

CLOZAPINE;

AGE DISTRIBUTION; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; HUMAN; LOW DRUG DOSE; PARKINSONISM; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 4644240092     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2004.04.007     Document Type: Article

References (14)

1. Fernandez H.H., Friedman J.H. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs. 11:(6):1999;467-483
2. Friedman J.H., Factor S.A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 15:(2):2000;201-211
3. Liebert K.A.M.J., Caley C.F. New Onset diabetes and atypical antipsychotics. Eur Neuropsychol. 11:2001;25-32
4. Mir S., Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol. 16:(2):2001;63-73
5. Hagg S., Joelsson L., Mjorndal T., Spigset O., Oja G., Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 59:(6):1998;294-299
6. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 157:(6):2000;975-981
7. Wirshing D.A., Pierre J.M., Eyeler J., Weinbach J., Wirshing W.C. Risperidone-associated new-onset diabetes. Biol Psychiatry. 50:(2):2001;148-149
8. Sobel M., Jaggers E.D., Franz M.A. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry. 60:(8):1999;556-557
9. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 340:(10):1999;757-763
10. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 353:(9169):1999;2041-2042
11. Factor S.A., Friedman J.H. The emerging role of clozapine in the treatment of movement disorders. Mov Disord. 12:(4):1997;483-496
12. CDC. National Health and Nutrition Examination Survey 1999-2000 data files. Available at http://www.cdc.gov/nchs/about/major/nhanes/NHANES99_00.htm; 2000.
13. Sowell M.O., Mukhopadhyay N., Cavazzoni P., Shankar S., Steinberg H.O., Breier A., et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 87:(6):2002;2918-2923
14. Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 26:(Suppl. 1):2003;S5-S20